Assessing the Impact of Pioglitazone on Fibrosis Progression amongst People with Type 2 Diabetes Mellitus (T2D): A Retrospective, Multi-centric Real-World Study in Indian Population

Authors: Gupta M and Chavda V

DOI: 10.23880/phoa-16000300

Volume 9, Issue 1

Abstract

Background: NAFLD (Non-Alcoholic Fatty Liver Disease) or metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver disorders and is the primary cause of chronic liver disease worldwide. The present study seeks to evaluate the effect of Pioglitazone on fibrosis progression, assessed by Fibrosis 4 (FIB-4) in individuals with type 2 diabetes mellitus (T2D).
Materials and Methods: In the present two-center retrospective study, adults with T2D who had at least 2 visits and 2 FIB4 values measured at least 90 days apart (from April 2021 to May 2024) were enrolled. Data was analyzed for descriptive statistics and compared for significance between groups. Statistical differences between the groups were determined by applying the Wilcoxon Signed-Rank Test and paired t-test. Results: 54 individuals with a mean age of 57.5 years (±12.7) were included for analysis. HbA1c [from 8.93% to 7.58% (p<0.01)] significantly improved while the BMI remained unchanged. Mean FIB-4 scores also significantly dropped from 1.99 at baseline to 1.54 at follow-up (p<0.01). FIB-4 scores declined from baseline in both the indeterminate and high-risk groups.

Keywords: Type 2 Diabetes Mellitus (T2D); Pioglitazone; Fibrosis-4 (FIB-4); HbA1c

View PDF